Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Recognizing the Rapidly Changing World of Surgical Oncology

September 29th 2025

Maurie Markman, MD, discusses the evolution of surgical oncology, from radical resections to multidisciplinary, minimally invasive, and neoadjuvant approaches.

ASCENT-GYN-01 Trial of Sacituzumab Govitecan Aims to Validate Clinical Utility of TROP2 ADCs in Pretreated Endometrial Cancer

September 26th 2025

Ramez N. Eskander, MD, discusses prior data supporting the ongoing investigation of sacituzumab govitecan as monotherapy in endometrial cancer.

Spotlighting Disease Prevention Efforts Alongside Treatment Breakthroughs Is Crucial for Endometrial Cancer Risk Reduction

September 23rd 2025

Brian Slomovitz, MD, spotlights key advancements in disease management and prevention during Gynecologic Cancer Awareness Month.

Dr Slomovitz on the Importance of Education on Disease Management and Prevention During Gynecologic Cancer Awareness Month

September 23rd 2025

Brian Slomovitz, MD, discusses the importance of education, prevention, and research in the context of gynecologic cancer awareness month.

Dr Farolfi on a Real-World Study of Bevacizumab Plus SOC Therapy in Cervical Cancer

September 19th 2025

Alberto Farolfi, MD, PhD, discusses bevacizumab plus SOC in advanced cervical cancer and no contraindications for antiangiogenic agents.

Advances in Surgical Approaches and Targeted Therapies Highlight Progress in Uterine Cancer

September 18th 2025

John P. Diaz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with uterine cancer.

Metformin Plus Letrozole and Abemaciclib Induces CRs in ER+ Recurrent Endometrial Cancer

September 16th 2025

The combination of metformin, letrozole, and abemaciclib was safe and active in patients with ER-positive recurrent endometrial cancer.

Neoadjuvant Tislelizumab Plus Chemo Drives Responses in Locally Advanced Cervical Cancer

September 15th 2025

Neoadjuvant tislelizumab plus chemotherapy yielded responses in locally advanced cervical cancer.

Dr Moore on the Evolution of Treatment Strategies for Advanced Endometrial Cancer

September 12th 2025

Kathleen N. Moore, MD, MS, discusses how standard-of-care treatment strategies for advanced recurrent endometrial cancer have improved over time.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Lunresertib and Other PKMYT1 Inhibitors Show Promise in Gynecologic Malignancies

September 5th 2025

Alison Schram, MD, discusses the potential clinical utility of PKMYT1-targeted agents in gynecologic malignancies.

Dr Diaz on the Importance of Early Recognition for Optimal Uterine Cancer Management

September 4th 2025

John P. Diaz, MD, discusses the importance of uterine cancer recognition and treatment optimization in the context of Gynecologic Cancer Awareness Month.

Tisotumab Vedotin Approved in Hong Kong for Recurrent or Metastatic Cervical Cancer

September 3rd 2025

Tisotumab vedotin is cleared in Hong Kong for the treatment of select patients with cervical cancer.

Development to Discontinue for ZW171 in Gynecologic, Thoracic, and GI Cancer

September 2nd 2025

The development of ZW171 for gynecologic, thoracic, and GI cancers is being discontinued.

Revisit Every OncLive On Air Episode From August 2025

September 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer

August 26th 2025

The FDA has granted breakthrough therapy designation to rinatabart sesutecan for the treatment of patients with advanced or recurrent endometrial cancer who have disease progression on or following standard-of-care therapy.

Dr Farolfi on Real-World Outcomes With Bevacizumab Plus SOC in Cervical Cancer

August 25th 2025

Alberto Farolfi, MD, PhD, discusses real-world findings with bevacizumab plus platinum-based chemotherapy and pembrolizumab in advanced cervical cancer.

Dr Mayadev on Using PD-L1 TAP as a Predictive Biomarker for Locally Advanced Cervical Cancer

August 18th 2025

Jyoti Mayadev, MD, discusses the clinical significance of tumor area positivityas a predictive biomarker in locally advanced cervical cancer.

Dr Duska on Pembrolizumab Plus Chemoradiotherapy in Cervical Cancer

August 11th 2025

Linda R. Duska, MD, MPH, discusses the background of the phase 3 KEYNOTE-A18 trial of pembrolizumab plus chemoradiotherapy in cervical cancer.

Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer

August 11th 2025

Extended follow-up showed sintilimab plus anlotinib yielded durable efficacy and tolerability in PD-L1–positive recurrent/metastatic cervical cancer.